Pharmacotherapy of borderline personality disorder

Journal of Clinical Psychiatry

Volumn 58, Issue SUPPL. 14, 1997, Pages 48-52

  Hirschfeld, Robert M A ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; CARBAMAZEPINE; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; PHENELZINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRIFLUOPERAZINE; VENLAFAXINE;

BORDERLINE STATE; CLINICAL TRIAL; DRUG CHOICE; DRUG EFFICACY; DRUG POTENCY; HUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; TREATMENT PLANNING;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; BORDERLINE PERSONALITY DISORDER; CLINICAL TRIALS; CYCLOHEXANOLS; FEMALE; HUMANS; LITHIUM; MALE; MONOAMINE OXIDASE INHIBITORS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0031439545     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Gunderson JG, Phillips KA. Personality disorders. In: Kaplan HI, Sadock BJ, eds. Comprehensive Textbook of Psychiatry/VI, vol 2. 6th ed. Baltimore, Md: Williams & Wilkins; 1995:1425-1461
2. Soloff PH. Psychopharmacologic therapies in borderline personality disorder. In: Tasman A, Hales RE, Frances AJ, eds. Review of Psychiatry, vol 8. Washington, DC: American Psychiatric Press; 1989:65-83
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
4. Widiger TA, Frances AJ. Epidemiology, diagnosis, and comorbidity of borderline personality disorder. In: Tasman A, Hales RE, Frances AJ, eds. Review of Psychiatry, vol 8. Washington, DC: American Psychiatric Press; 1989:8-24
5. Sheard MH, Marini JL, Bridges CL, et al. The effect of lithium on impulsive aggressive behavior in man. Am J Psychiatry 1976;133:1409-1413
6. Rifkin A, Quitkin F, Carrillo C, et al. Lithium carbonate in emotionally unstable character disorder. Arch Gen Psychiatry 1972;27:519-523
7. Gardner DL, Cowdry RW. Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder. Am J Psychiatry 1986;143: 519-522
8. Wilcox JA. Divalproex sodium as a treatment for borderline personality disorder. Ann Clin Psychiatry 1995;7:33-37
9. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder. Arch Gen Psychiatry 1988;45:111-119
10. Liebowitz MR, Quitkin FM, Stewart JW, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988;45:129-137
11. Parsons B, Quitkin FM, McGrath PJ, et al. Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacol Bull 1989;25:524-534
12. Soloff PH, Cornelius J, George A, et al. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry 1993;50: 377-385
13. Soloff PH, George A, Nathan S, et al. Progress in pharmacotherapy of borderline disorders. Arch Gen Psychiatry 1986;43:691-697
14. Salzman C, Wolfson AN, Schatzberg A, et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 1995;15:23-29
15. Markovitz PJ, Calabrese JR, Schultz SC, et al. Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry 1991; 148:1064-1067
16. Cornelius JR, Soloff PH, Perel JM, et al. A preliminary trial of fluoxetine in refractory borderline patients. J Clin Psychopharmacol 1991;11:116-120
17. Nordern MJ. Fluoxetine in borderline personality disorder. Prog Neuropsychopharmacol Biol Psychiatry 1989;13:885-893
18. Kavoussi RJ, Liu J, Coccaro EF. An open trial of sertraline in personality disordered patients with impulsive aggression. J Clin Psychiatry 1994;55: 137-141
19. Markovitz PJ, Wagner SC. An open trial of venlafaxine in borderline personality disorder. Presented at the 35th annual meeting of the New Clinical Drug Evaluation Unit; May 31-June 3, 1995; Orlando, Fla